BrainScan

BrainScan Financial Leverage

The Financial Leverage (Equity Multiplier) of BrainScan (BSN.WA) as of Oct 21, 2026 is -1.07. In the previous year, Financial Leverage (Equity Multiplier) was -2.36 — a change of -54.80% (higher).

Financial Leverage

-1.07

YoY

-54.80%

Last updated:

Financial Leverage (Equity Multiplier) of BrainScan is 2025 -1.07 . Financial Leverage (Equity Multiplier) of BrainScan was 2024 -2.36 . It decreases by -54.80% higher compared to the previous year.

The BrainScan Financial Leverage history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Financial Leverage
Date
Financial Leverage
Jan 1, 2022
1.46 PLN
Jan 1, 2023
1.07 PLN
Jan 1, 2024
-2.36 PLN
Jan 1, 2025
-1.07 PLN
The BrainScan Financial Leverage history
YEARFinancial LeverageYoY
-1.07-54.80%
-2.36-320.81%
1.07-26.67%
1.46—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

BrainScan Stock analysis

What does BrainScan do? BrainScan SA generates revenue through its flagship product, the BrainScan CT system, which is used by medical facilities to optimize brain imaging diagnostics. The system delivers head tomography analysis results in under three minutes, identifying pathologies like tumors and hemorrhages through AI-driven deep learning. Hospitals and clinics purchase the system to accelerate diagnostic processes and improve treatment decision-making. The company's AI technology enables automatic patient triage, enhancing the efficiency of medical interventions. The BrainScan CT system is designed for use in healthcare settings where rapid diagnosis is critical, such as emergency departments and specialized neurology clinics. Medical institutions in Poland and potentially other European markets are the primary customers, leveraging the system's ability to shorten the time between examination and treatment initiation. The company's focus on AI-powered diagnostics positions it as a solution for facilities seeking to modernize their imaging workflows. BrainScan SA's revenue model relies on the sale of its AI diagnostic system to healthcare providers, with the BrainScan CT system being the core product. The system's unique value proposition lies in its speed and accuracy, offering results faster than traditional methods. By automating the analysis of brain imaging, the system reduces the workload on radiologists and improves patient outcomes through timely interventions. BrainScan is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BrainScan stock

Financial Leverage (Equity Multiplier) of BrainScan is -1.07 in 2025.

Financial Leverage (Equity Multiplier) of BrainScan changed from -2.36 to -1.07, representing a -54.80% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Financial Leverage (Equity Multiplier) BrainScan since 2006 – with annual values, charts, and detailed analysis.

Financial leverage, also known as the equity multiplier, measures total assets relative to equity. Higher leverage amplifies both returns and risks.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Financial Leverage (Equity Multiplier)'s BrainScan with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — BrainScan

All Key Metrics — BrainScan